Core Laboratories (CLB) Current Deferred Revenue (2022 - 2026)

Core Laboratories' Current Deferred Revenue history runs 5 years deep, the most recent figure standing at $4.7 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 51.82% year-over-year to $4.7 million in Q1 2026; TTM through Mar 2026 was $4.7 million, a 51.82% decrease from a year earlier, with the FY2025 full-year figure at $5.6 million, down 40.51% from the prior year.
• Current Deferred Revenue retreated to $4.7 million in Q1 2026 per CLB's latest filing, from $5.6 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $9.8 million in Q1 2025 and bottomed at $4.6 million in Q3 2023.
• The 5-year median for Current Deferred Revenue is $5.6 million (2025), against an average of $6.5 million.
• Across the five-year window, Current Deferred Revenue soared 96.26% in 2024 and tumbled 51.82% in 2026, its largest moves.
• Year by year, Current Deferred Revenue stood at $5.9 million in 2022, then declined by 19.98% to $4.8 million in 2023, then surged by 96.26% to $9.3 million in 2024, then tumbled by 40.51% to $5.6 million in 2025, then slipped by 15.2% to $4.7 million in 2026.
• Per Business Quant, the three latest CLB Current Deferred Revenue figures stand at $4.7 million (Q1 2026), $5.6 million (Q4 2025), and $7.3 million (Q3 2025).